Download presentation
Presentation is loading. Please wait.
Published byLeo Verlinden Modified over 6 years ago
1
A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy Irene M. Lips, M.D., Carla H. van Gils, Ph.D., Alexis N.T.J. Kotte, Ph.D., Monique E. van Leerdam, M.D., Ph.D., Stefan P.G. Franken, M.D., Uulke A. van der Heide, Ph.D., Marco van Vulpen, M.D., Ph.D. International Journal of Radiation Oncology • Biology • Physics Volume 83, Issue 2, Pages (June 2012) DOI: /j.ijrobp Copyright © 2012 Elsevier Inc. Terms and Conditions
2
Fig. 1 CONSORT patient flow diagram.
International Journal of Radiation Oncology • Biology • Physics , DOI: ( /j.ijrobp ) Copyright © 2012 Elsevier Inc. Terms and Conditions
3
Fig. 2 Pretreatment complaints and acute toxicity, as measured by the Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE v.3). International Journal of Radiation Oncology • Biology • Physics , DOI: ( /j.ijrobp ) Copyright © 2012 Elsevier Inc. Terms and Conditions
4
Fig. 3 Proportions of patients per treatment group showing clinically meaningful changes in quality of life (QoL) scores between baseline and 1 month after treatment. Patients are classified as having worsened QoL (>10% worsening in QoL scores), stable QoL (<10% change in QoL scores), or improved QoL (>10% improvement in QoL scores). Only the six QoL items with the largest differences in worsened QoL between the magnesium oxide arm and the placebo arm are shown. RAND-36 = RAND-36 generic health survey; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer core questionnaire; EORTC QLQ-PR25 = EORTC prostate cancer module. International Journal of Radiation Oncology • Biology • Physics , DOI: ( /j.ijrobp ) Copyright © 2012 Elsevier Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.